Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
- 20 July 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (21), 2699-2707
- https://doi.org/10.1200/jco.2013.49.1514
Abstract
To gain insight into the prevalence and severity of chemotherapy-induced neuropathy and its influence on health-related quality of life (HRQOL) in a population-based sample of colorectal cancer (CRC) survivors 2 to 11 years after diagnosis. All alive individuals diagnosed with CRC between 2000 and 2009 as registered by the Dutch population-based Eindhoven Cancer Registry were eligible for participation. Eighty-three percent (n = 1,643) of patients filled out the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 and the EORTC QLQ Chemotherapy-Induced Peripheral Neuropathy 20. The five neuropathy subscale–related symptoms that bothered patients with CRC the most during the past week were erectile problems (42% of men), trouble hearing (11%), trouble opening jars or bottles (11%), tingling toes/feet (10%), and trouble walking stairs or standing up (9%). Additionally, patients who received oxaliplatin more often reported tingling (29% v 8%; P = .001), numbness (17% v 5%; P = .005), and aching or burning pain (13% v 6%; P = .03) in toes/feet compared with those not treated with chemotherapy. They also more often reported tingling toes/feet (29% v 14%; P = .0127) compared with those treated with chemotherapy without oxaliplatin. Those with many neuropathy symptoms (eg, upper 10%) reported statistically significant and clinically relevant worse HRQOL scores on all EORTC QLQ-C30 subscales (all P < .01). Two to 11 years after diagnosis of CRC, neuropathy-related symptoms are still reported, especially sensory symptoms in the lower extremities among those treated with oxaliplatin. Because neuropathy symptoms have a negative influence on HRQOL, these should be screened for and alleviated. Future studies should focus on prevention and relief of chemotherapy-induced neuropathy.Keywords
This publication has 37 references indexed in Scilit:
- The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findingsAnnals of Oncology, 2012
- Most colorectal cancer survivors live a large proportion of their remaining life in good healthCancer Causes & Control, 2012
- Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patientsSupportive Care in Cancer, 2011
- The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CASupportive Care in Cancer, 2011
- Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of ReversibilityThe Oncologist, 2011
- Surviving Chemotherapy for Colon Cancer and Living with the ConsequencesJournal of Palliative Medicine, 2010
- Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available toolsEuropean Journal of Cancer, 2010
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- The self‐administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services researchArthritis Care & Research, 2003
- Neurotoxic Complications of Chemotherapy in Patients with CancerDrugs, 2003